Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (181-190 of 300) with videos related to

Pageof 30
Sort By:
Blood|November 18, 2018
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016Xiaoyu Qu, Hongli Li, Rita M Braziel, et al.
Leukemia Research|December 5, 2003
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivoJonathan W Friedberg, Danielle A Dong, Sigui Li, et al.
British Journal of Haematology|April 7, 2009
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomasJennifer R Brown, Jonathan W Friedberg, Yang Feng, et al.
Blood|February 7, 2019
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative studyEric D Hsi, Hongli Li, Andrew B Nixon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Follicular lymphoma in the United States: first report of the national LymphoCare studyJonathan W Friedberg, Michael D Taylor, James R Cerhan, et al.
Leukemia & Lymphoma|January 25, 2013
Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes databaseKarim E Abou-Nassar, Ann Vanderplas, Jonathan W Friedberg, et al.
JACC. Cardiooncology|May 22, 2024
Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin LymphomaJenica N Upshaw, Jason Nelson, Benjamin Sweigart, et al.
Journal of the National Cancer Institute|December 18, 2016
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma ResearchGrzegorz S Nowakowski, Kristie A Blum, Brad S Kahl, et al.
The Lancet. Oncology|July 22, 2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyAnas Younes, Catherine Thieblemont, Franck Morschhauser, et al.
Leukemia & Lymphoma|January 14, 2016
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520Soham D Puvvada, Hongli Li, Lisa M Rimsza, et al.
Pageof 30

Showing results (181-190 of 300) with videos related to

Sort By:
Pageof 30
Blood|November 18, 2018
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016Xiaoyu Qu, Hongli Li, Rita M Braziel, et al.
Leukemia Research|December 5, 2003
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivoJonathan W Friedberg, Danielle A Dong, Sigui Li, et al.
British Journal of Haematology|April 7, 2009
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomasJennifer R Brown, Jonathan W Friedberg, Yang Feng, et al.
Blood|February 7, 2019
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative studyEric D Hsi, Hongli Li, Andrew B Nixon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Follicular lymphoma in the United States: first report of the national LymphoCare studyJonathan W Friedberg, Michael D Taylor, James R Cerhan, et al.
Leukemia & Lymphoma|January 25, 2013
Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes databaseKarim E Abou-Nassar, Ann Vanderplas, Jonathan W Friedberg, et al.
JACC. Cardiooncology|May 22, 2024
Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin LymphomaJenica N Upshaw, Jason Nelson, Benjamin Sweigart, et al.
Journal of the National Cancer Institute|December 18, 2016
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma ResearchGrzegorz S Nowakowski, Kristie A Blum, Brad S Kahl, et al.
The Lancet. Oncology|July 22, 2014
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b studyAnas Younes, Catherine Thieblemont, Franck Morschhauser, et al.
Leukemia & Lymphoma|January 14, 2016
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520Soham D Puvvada, Hongli Li, Lisa M Rimsza, et al.
Pageof 30